New Data Analyses from Phase 3 Study of Investigational Gene Therapy Nadofaragene Firadenovec Presented at Society of Urologic Oncology Annual Meeting Adds More Evidence to Data Published in Lancet Oncology

Uncategorized
  • Low rate of cystectomy and delayed time to cystectomy among patients who achieved complete response
  • Patient characteristics or prior treatment history do not influence response
  • Significant anti-adenovirus antibody response does not appear to affect patient outcomes

San Francisco, CA (UroToday.com) — FerGene Inc. announced new data analyses results from the landmark Phase 3 clinical trial evaluating nadofaragene firadenovec (rAd-IFN/Syn3) for the treatment of patients with high-grade, Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC). In the study, published in The Lancet Oncology on November 27, patients received nadofaragene firadenovec, an intravesical therapy given once every three months that are believed to target the patient’s own bladder wall cells to enhance the body’s natural defenses to fight cancer.1 The three new analyses from the pivotal study presented during the Society of Urologic Oncology (SUO) 21st Annual Meeting provide more evidence that nadofaragene firadenovec is a promising option for patients where BCG has failed.

X